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Abstract 
Background: Rheumatoid arthritis (RA) is a complex autoimmune disease 
involving gene-environment interactions. Different subtypes of RA, based on the 
presence of specific antibodies, differ in each etiology. Interacting effects have 
been found in HLA-DRB1 shared epitope alleles with smoking, in relation to the 
increased risk of one subgroup of RA.   
Aims: To identify interactions involving imputed amino acids in HLA proteins 
and smoking regarding risk of developing serologically defined subgroups of 
rheumatoid arthritis. 
Methods: Two materials respectively including 3000 and 4337 individuals aged 
18-70 recruited during 1996-2009 from the EIRA study, a population-based case-
control study were used for this investigation. Serum antibodies against cyclic 
citrullinated peptide (CCP) were examined to decide subtypes of RA. We used 
8961 genetic markers in HLA that were imputed from a reference panel based on 
individuals of European decent. Lifestyle variables including smoking were 
obtained from questionnaires. We used logistic regression to estimate odds ratios 
regarding risk of developing different subgroups of RA. We used attributable 
proportion to estimate interaction between genetic markers and smoking with 
consideration taken to genetic models. 
Results: 48 amino acid positions in HLA-DRB1, DQA1, DQB1 regions were 
associated with interacting effects with smoking in ACPA-positive RA. Results 
are similar in two materials, and 22 remained after controlling for shared epitope 
alleles in DRB1. No SNPs or interacting effect were found significant in ACPA-
negative RA after correction for multiple testing.   
Conclusion: The study found interacting effects in HLA proteins independent of 
shared epitope alleles with smoking, in relation to the risk of development of 
ACPA-positive RA. 
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1. Background 
1.1   Rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disease that is believed to have a complex 
etiology involving environmental and genetic factors. 1  The prevalence of RA differs 
geographically, ranging from 0.5% to 1%, and it is two to three times more frequent in 
women as compared to men. 2  A twin study indicated that heritability accounted for 
approximately 65% of RA, by comparing the concordance rates among monozygotic twins 
with dizygotic twins. 3  Despite the findings in genome-wide association (GWA) studies, 
rheumatoid arthritis is still regarded as a complex disease in that the T cell-mediated immune 
regulation can be stimulated by environmental factors. 4 , 5  The overexpression of tumor 
necrosis factor (TNF) is suggested to be the main cause for synovial inflammation and joint 
destruction.6 However, the etiology of RA remains unclear, especially how genetic factors 
may interact with environmental factors in immune responses that consequently cause the 
inflammation and damage of the joints in the body. 
 
1.2   Subtypes of rheumatoid arthritis 
Previous study indicated that the diagnosis of “rheumatoid arthritis” was a set of diseases 
with different etiology but similar symptoms.1 Thus, it is natural to consider distinct types of 
the disease simultaneously when it comes to the pathogenesis of RA, through integrating 
environmental and genetic risk factors.  
A recent subdivision is based on the presence of antibodies against cyclic citrullinated 
peptide (anti-CCP), or anti-citrullinated peptide antigens (ACPA) in the blood. ACPA is an 
anti-body targeting citrullinated peptide, while citrullination is a product of a posttranslational 
modification of the amino acid arginine. This subdivision has been proved to have high 
specificity regarding RA.7 Presence of ACPA is considered to be stable over time in this 
subgroup of RA patients. Approximately 70% of RA patients have anti-citrullinated peptide 
antigens.1 Also, antibodies to the immune dominant citrullinated α-enolase CEP-1 epitope, 
which is a subset of the ACPA group, have been reported to be associated with the gene-
environment interaction. 8  Besides the previously described groups, there are some other 
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traditional subdivisions, such as separating RA based on the presence of an antibody complex 
called rheumatoid factor (RF). 
 
1.3   Predictors for rheumatoid arthritis 
Several environmental exposures with increased risk for RA have been identified such as 
smoking, parity, exposure to mineral oil, and exposure to silica. 9 , 10 , 11 , 12  Among those, 
smoking is the most established one, and has been associated with certain types of RA, with 
an observed relative risk up to 2.13 
On the other hand, over fifty genetic risk loci have been discovered through genome-
wide approach as well as candidate-gene approach.14,15,16 A recent GWA study indicated that 
the strong association between the major histocompatibility complex (MHC) and ACPA-
positive disease could be explained by amino acids in human leukocyte antigen molecule 
(HLA) proteins located in peptide-binding grooves. 17  The gene coding for HLA in 
chromosome 6 is believed to play an important role in the immune system as a presenter of 
foreign substances as well as autogenic substances. However, the main genetic effects of 
single nucleotide polymorphisms (SNPs) do not take into account gene-environment 
interactions that are considered to be important for the occurrence of complex diseases. 
So far, a strong interaction between smoking and HLA-DRB1 “shared epitope” (SE) 
alleles has been observed in relation to ACPA-positive RA susceptibility.18,19 These studies 
used a candidate-gene approach, but still less is known about the gene-environment 
interaction on a genome-wide level. A recent published abstract described the gene-
environment interaction between smoking and SNPs concerning two subsets of RA in a 
genome-wide scale.20 The findings show that all SNPs interacting with smoking are located 
in the HLA region, especially the HLA class II region. In the light of these findings, we can 
narrow down our initial scope to chromosome 6, where MHC and HLA are located, and thus 
apply a genome-wide analysis approach to a candidate region. 
 
1.4   HLA and autoimmune diseases 
The human leukocyte antigen (HLA) genes are the genetic basis of the major 
histocompatibility complex (MHC) molecules, located in chromosome 6 
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and traditionally have three classifications: HLA-class I, class II, and class III genes. Among 
those, the class II genes include HLA-DP, -DQ, -DR (Fig 1a). HLA class II molecules, the 
expression products of class II genes, have functions in recognizing and binding peptides on 
the surface of antigen-presenting cells (APCs) (Fig 1b). As long as a peptide is engaged with 
MHC molecule, simultaneously binding to T-cell receptor (TCR), the 'first signal' (MHC-Ag-
TCR) of T-cell activation is evoked (Fig 1c). Normally, matured T-cell response has a 
tolerance for auto-antigen, however in RA patients, this tolerance has been destroyed and the 
T-cell mediates self-active signals. Consequently, the immune system is attacking the own 
tissues as if they were foreign antigens. 
 
1.5   Methods for gene-environment interactions 
When estimating interaction we need to take into account the diverse definitions of 
interaction. In this study, we primarily use additive interaction to evaluate the interaction 
between amino acid polymorphisms and smoking, as suggested by Rothman. 21  The 
attributable proportion (AP) owing to interaction is calculated in order to quantify the amount 
of excess risk for RA. Attributable proportion is the proportion of the incidence among 
persons exposed to two interacting factors that is attributable to the interaction per se. That 
means, AP reflects their joint effect beyond the sum of their independent effects.  
There are mainly two strategies in the context of gene environment interaction studies.22 
One strategy is the parametric or semi-parametric approach, which requires intrinsical 
models, for instance, a regression framework. This approach is usually chosen when 
researchers aim to screen for unknown interaction factors, to test for marginal effects, or to 
test for interaction per se. An alternative strategy is the agnostic approach. This model-free 
approach is released from classical hypothesis testing procedure, and many data-mining 
approaches are borrowed to fit the high-dimensionality and large-scale data collections. In the 
current study, we utilized the regression model to scan for possible interacting effects, in 
order to allow for the inclusion of matching variables, confounders and effect modifiers.  
  
2. Aims 
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In this study, we take a genome-wide analysis approach in chromosome six aiming to 
examine the interactions involving imputed amino acid polymorphisms in HLA proteins and 
smoking in the development of serologically defined subtypes of rheumatoid arthritis.  
The research questions are: 1) Is there any interaction between imputed amino acids in 
HLA and smoking regarding risk of developing rheumatoid arthritis; 2) Is there any 
difference in HLA amino acids and smoking interactions between ACPA-positive and ACPA-
negative RA cases; 3) Is there any difference in HLA amino acids and smoking interactions if 
we use different genetic models (dominant, recessive, and co-dominant models); 4) Is there 
any independent interaction within HLA conditioning on HLA-DRB1 shared epitope (SE) 
alleles?  
 
3. Methods 
3.1   Data 
This study was based on the Epidemiological Investigation of Rheumatoid Arthritis (EIRA), 
which was a large population-based epidemiological study conducted in Sweden. EIRA was a 
case-control study including newly diagnosed individuals aged 18-70 since May 1996 and 
still ongoing, and consisting of two sets of participants --- EIRA I and EIRA II. Cases were 
defined as individuals newly diagnosed with RA according to the American College of 
Rheumatology (ACR) criteria of 1987, while controls were randomly selected from a national 
population register to match cases in terms of age, gender and residential area at the time of 
diagnosis.23 For EIRA I all the controls were individually matched, and for EIRA II they 
were probabilistically matched. By this approach, adjusted odds ratios can be interpreted as 
estimates of incidence rate ratio, since incident cases and population based controls were 
recruited as soon as a new case occurred in the source population. Details about the study 
design have been reported elsewhere.13 
In this study, we included all individuals recruited in EIRA until 2009 comprising two 
subgroups of the two generations of EIRA studies. The first material included a total number 
of 3000 individuals. 1921 individuals newly diagnosed with RA were selected as cases and 
1079 healthy individuals were selected as controls. The second material included 4337 
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individuals, among which 2481 were cases and 1856 were controls. Quality control has been 
done to exclude individuals with for instance disorder sex information or outlying missing 
genotyping rates. There was no significant difference between individuals that were included 
and were removed from the study in some important characteristics. 
 
3.2   Biological parameters and imputation 
Biological data including ACPA status and chromosome six genotypic sequences were 
obtained. Serum antibodies were analyzed through using ELISA (Immuno-scan CCPlus, 
Euro-Diagnostica) to determine ACPA status. 25 U/ml was set as the cut-off for ACPA 
positivity. Genotyping for HLA sequences was conducted using blood sample through the 
sequence-specific primer polymerase chain reaction (PCR) method, as described in previous 
publication.18 Shared epitope alleles were defined as DRB1*01, DRB1*04, and DRB1*10.24 
These alleles that are associated with ACPA-positive RA were denoted as „shared epitope‟, in 
that they share a common amino acid sequence (70QRRAA74, 70RRRAA74, or 70QKRAA74) 
within the HLA-DRB1 region.25 
However, pinpointing the candidate loci within HLA is challenging due to the structural 
complexity and the extensive linkage disequilibrium (LD) characteristic of the MHC. 26 
Hence, we imputed classical HLA alleles and the corresponding amino acid sequences 
utilizing reference data collected by the Type 1 Diabetes Genetics Consortium (T1DGC) 
based on European decent. For the first material of 3000 individuals, we used a set of 
genome-wide dense markers from a genome-wide association study. For the second material 
of 4337 individuals, we utilized the Immunochip markers, which were concentrated on 
immunologic interested regions based on observations from different autoimmune diseases 
such as RA, Multiple sclerosis (MS) and others. If we use capital letters (A) to denote major 
alleles and use lowercase letters (a) to denote minor alleles, we can obtain probabilities that 
take the uncertainty in the imputation procedure into account for each of the three genotypes: 
the homozygous reference genotype (A/A), the heterozygous genotype (A/a), and the 
homozygous variant genotype (a/a). A threshold was decided to determine the imputed 
genotypes of each marker. We encoded exhaustive groups of loci with high polymorphisms in 
the reference panel as biallelic markers. Imputation was performed through using BEAGLE.27 
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Cases and controls were imputed together for each material. Imputation accuracy and 
genotype rate were assessed. 
Data quality assessment and control were carried out among both samples and markers in 
order to minimized false positives. We used the following criteria to filter out low-quality 
markers: marker call rates less than 95% in either cases or controls; minor allele frequency 
(MAF) less than 0.01 in either cases or controls; Hardy-Weinberg equilibrium p-value less 
than 1×10-5 in controls. Meanwhile, we removed subjects with posterior probability of 
genotype < 0.99, showing evidence of relatedness, showing evidence of possible DNA 
contamination, and with non-European ancestry. All the quality control procedures were 
performed in PLINK (version 1.07).28 
 
3.3   Smoking and covariates information 
Information regarding lifestyle factors including smoking was obtained through self-reported 
questionnaire. There were five categories for cigarette smoking: never smokers; current 
smokers; ex-smokers; non-regular smokers; and other types of smokers. Only participants of 
“never smokers” were considered as “never smoker”, and other participants were classified as 
“ever smokers”. Exposures were only considered before the first RA symptoms occurred 
among cases, and the same time period was applied to the corresponding controls. Baseline 
characteristics including age, sex, and living area were also collected through questionnaires. 
Age was collected as continuous, and divided into 10 categories. Living area had 20 
categories in the original data, and was classified as either „Stockholm‟ or „Outside 
Stockholm‟. 
  
3.4   Genetic models 
Now that genotypes were obtained from imputation, we applied genetic models in which 
genotypes were observed as alleles, and further related to phenotypes. Given that single 
major locus was considered as a functional unit, three genetic models were performed to each 
marker: dominant, recessive, and co-dominant model. Assuming minor alleles (a) represented 
risk factors for RA, a dominant mode indicates that subjects carrying either one or two copies 
of minor allele (A/a; a/a) would be classified as present of a specific genetic risk factor. In the 
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recessive model, only subjects with two copies of minor allele (a/a) would be classified as 
present of genetic risk factor. Then, in the co-dominant model, each additional copy of minor 
alleles would be regarded as genetic risk factor, as compared to the homozygous reference 
group (A/A). 
 
3.5   Statistical analysis 
DNA samples and markers that may introduce bias were identified and removed as described 
above. A chi-square test was performed to evaluate the association of selected HLA allelic 
genotypes and their corresponding amino acid sequences in relation to ACPA-positive and 
ACPA-negative RA respectively. 
We used logistic regression models to test the multiplicative interaction between HLA 
allelic genotypes and smoking in relation to the development of RA. Log odds can be 
calculated for each biallelic marker in the following model: 
𝑙𝑜𝑔𝑖𝑡(𝐴𝑙𝑙𝑒𝑙𝑒𝛼) = 𝜃 + 𝛽𝐺,𝛼 ∙ 𝐺𝛼 + 𝛽𝐸,𝛼 ∙ 𝐸 + 𝛽𝐼,𝛼 ∙ 𝐺𝛼 ∙ 𝐸 + 𝛽𝐶𝑜𝑣 ∙ 𝐶𝑜𝑣 
where 𝛼 indicates the specific allele being tested; 𝛽𝐺,𝛼  is the parameter for allele additive 
effect, while 𝛽𝐸,𝛼  is the parameter for environmental effect, and 𝛽𝐼,𝛼  for gene-environment 
interaction effect. 𝐺𝛼 means the dosage of allele 𝛼. E equals 1 in the presence of smoking 
history, and 0 otherwise. Covariates that were included in the model were age, sex, and living 
area. The logistic regression model was applied to each biallelic marker. The null hypothesis 
is that 𝛽𝐼,𝛼 = 0. Correction effects were added to the model at later stage. 
 Then we tested additive interaction by measuring the attributable proportion (AP) 
together with 95% CI as follows: 
RERI = RR11 - RR10 - RR01 + 1, 
AP = RERI/RR11 
RR11 represents the relative risk when both genetic and environmental risk factors are 
present; RR10 means the relative risk in the presence of genetic factor while in the absence of 
environmental factor; and RR01 correspondingly means the relative risk in the absence of 
genetic factor while in the presence of environmental factor. We assume the baseline situation 
in which both factors are unexposed to be RR00 = 1. Different genetic models were applied as 
described above. The null hypothesis is that AP = 0. All the interaction tests were performed 
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in ACPA-positive and ACPA-negative RA respectively. Adjustment was made for age, sex, 
and living area. Because so many tests were performed, we corrected for multiple testing 
through Bonferroni correction. P-values were adjusted using Bonferroni correction, and we 
used 0.05 divided by the number of markers in the test as the p-value threshold for 
significance. We excluded markers with cell frequency less than 5, in order to minimize the 
potential false positive. 
HLA-DRB1 shared epitope (SE) alleles that confer susceptibility to RA, are strongly 
linked with adjacent alleles, due to the unique biochemical structure of HLA class II region 
(DR, DQ, DP). Hence, we further assessed the independent effects through conditioning the 
logistic models on shared epitope in HLA-DRB1. The dichotomized status of sheared epitope 
alleles used a dominant genetic model. Information regarding shared epitope was included as 
covariate in the model. 
Genetic data were analyzed using Haploview 4.2, and R package car.29 ,30 Statistical 
software including R (version 2.14.1) and SAS (version 9.2) were used to perform statistical 
analysis. AP was calculated by the GEIRA program, a published program for calculating 
gene-environment and gene-gene interaction.31 
 
4 Ethical considerations 
This study analyses existing data collected as part of EIRA. A most visualized risk is the 
physical harm caused in the process of biological data collection. Sera and cells of 
participants were used for serologic analysis and DNA genotyping. Biological samples were 
obtained from cases during their first visit to the rheumatology department; while for 
controls, they were obtained from local health care units. Trained nurses were recruited to 
perform the work, and during the whole process, standard hygiene was monitored and 
ensured. 
Concerns about data safety should be mentioned. A chain of strict instructions was 
followed to ensure the data safety. Data were preserved in a way that only limited people had 
the access to it, and researchers had no access to personal identity numbers, name, address or 
any other information that could link the characteristics to a certain individual. 
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Psychological risk come from the questionnaire was limited, since the questions only 
covered lifestyle questions. Despite that one may answer differently if he or she was 
accompanied by someone, it was unlikely to cause any psychological or emotional risks. 
Information in this study is collected using an extensive questionnaire and blood samples. 
Hence, our application of data in this study will not cause any extra burden for participants. 
Informed consents were obtained from all subjects. This study was approved by 
Regional Ethics Committee of Stockholm (DNR 96-174, 2006/476-31/4). 
 
5 Results 
5.1   Baseline and clinical characteristics 
After quality control of genotyping data, we imputed binary 8961 SNP markers across MHC, 
including nucleotides, amino acid residues, and groups of nucleotides or amino acid residues. 
A total number of 1815 cases (60.5%) in the GWAS material, of which 1101 (36.7%) were 
APCA-positive RA cases. In the Immunochip material, a total of 2481 cases (57.2%) were 
used, of which 1590 (36.7%) were APCA-positive cases. A description on characteristics of 
all participants is provided in Table 1. No significant differences were found among 
participant categories in terms of sex, age, or living area. Smoking showed an increased risk 
for rheumatoid arthritis (GWAS material: p = 0.0007; Immunochip material: p < 0.0001). 
Shared epitope status was also different depending on subtypes of RA (GWAS material: p < 
0.0001; Immunochip material: p < 0.0001). 
 
5.2   Genotypes and RA association tests 
We first wanted to estimate the major genetic effect within HLA region in chromosome 6 in 
relation to ACPA status of RA. Each allele was used as a unit of analysis. In the GWAS 
material, strong associations were found between HLA genotypes and ACPA-positive RA, 
but not ACPA-negative RA. The markers with high associations were concentrated around 
HLA-DRB1 region (Fig 2a-b). On the other hand, in the Immunochip material, associations 
were found in both ACPA-positive and ACPA-negative RA cases. These identified markers 
mainly range from HLA-C to HLA-DRB1 region in chromosome 6 (Fig 2c-d). We used 
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genotypes with major allele frequencies as reference, and the odds ratios corresponding to 
genotypes with minor allele frequencies appeared both above and below 1, which indicating 
protective effects as well as increased risks among genotypes with minor allele frequencies. 
The most significant association for ACPA-positive RA was observed in HLA-DRB1 position 
13 (OR: 2.925, p = 2.616×10-104); while the most significant association for ACPA-negative 
RA showed in rs9268861 (OR: 1.433, p = 1.512×10-8). 
 
5.3   Multiplicative interactions between genotypes and smoking 
When we used the model framework described above to test for interactions in multiplicative 
scale, no markers were found to interact with smoking in ACPA-positive and ACPA-negative 
RA after Bonferroni correction, neither in GWAS data nor the Immunochip data (Fig 2).  
 
5.4   Additive interactions between genotypes and smoking 
First we tested for additive interactions from the dominant model. In the GWAS data, 103 
markers were detected in ACPA-positive RA, among which 45 were amino acid markers 
corresponding to 17 amino acids in HLA, including 16 amino acids in HLA-DRB1 and 1 
amino acid in HLA-DQA1: HLA-DRB1 position -25, -24, -16, 10, 11, 12, 13, 33, 37, 47, 96, 
120, 149, 180, 233; HLA-DQA1 position 34 (Table 2, Appendix Table). More markers were 
identified in the Immunochip data. 237 markers including 58 amino acid markers and 179 
SNPs were significant in the dominant model. These amino acids markers correspond to 22 
amino acid positions: HLA-DRB1 position -25, -16, 10, 11, 12, 13, 32, 37, 47, 67,70, 73, 74, 
96, 120, 149, 233; HLA-DQA1 position 34, 47, 56,76; HLA-DQB1 position 71 (Table 2, 
Appendix Table). All tests were adjusted for sex, age, and living area, and corrected for 
multiple testing. 
When we applied the recessive model to the GWAS material, 282 markers showed 
significant among ACPA-positive RA after Bonferroni correction, and 96 amino acid markers 
were corresponding to as many as 38 amino acids in HLA-DRB1, HLA-DQA1, and HLA-
DQB1: HLA-DRB1 position -24, 10, 11, 12, 13, 33, 37, 70, 74, 96, 98, 104, 120, 149, 180, 
233; HLA-DQA1 position 26, 40, 47, 50, 51, 53, 56, 76, 187, 215; HLA-DQB1 position -10, 
28, 30, 37, 46, 47, 52, 55, 71, 74, 140, 182 (Table 2, Appendix Table). Similarly, recessive 
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model showed more markers in Immunochip material, especially in DQA1 and DQB1. 56 
amino acid markers out of 207 significant markers were identified, corresponding to 34 
amino acid positions: HLA-DRB1 position -24, 11, 13, 33, 37, 67, 70, 73, 74, 96, 120, 180; 
HLA-DQA1 position 26,34, 40, 47, 50, 51, 53, 56, 76, 187; HLA-DQB1 position -10, 28, 30, 
37, 46, 47, 52, 55, 66, 67, 71, 74. 
And in the co-dominant model, 34 amino acids were identified within HLA among 
ACPA-positive RA in GWAS material: HLA-DRB1 position -25, -24, -16, 10, 11, 12, 13, 32, 
33, 37, 47, 70, 74, 96, 98, 104, 120, 149, 180, 233; HLA-DQA1 position 26, 34, 47, 50, 53, 
56, 76, 175, 187, 215; HLA-DQB1 position 30, 55, 140, 182 (Table 2, Appendix Table). In 
Immunochip material, co-dominant model covered almost all the markers identified in two 
previous models. A  total number of 356 markers including 96 amino acid markers were 
found, and corresponding to 42 amino acids: HLA-DRB1 position -25, -24,-16, 10, 11, 12, 
13, 32, 33, 37, 47, 67, 70, 73, 74, 96, 120, 149, 180, 233; HLA-DQA1 position 26,34, 40, 47, 
50, 51, 53, 56, 76, 187; HLA-DQB1 position -10, 28, 30, 37, 46, 47, 52, 55, 66, 67, 71, 74. 
The highest attributable proportion was observed in HLA-DRB1*0401 (AP: 0.814, 95% CI: 
0.630 - 0.998, p = 3.635×10-18), when co-dominant model was applied to the GWAS data. 
Interestingly, we observed 3 SNPs only showing effects with ACPA-positive RA when 
interaction with smoking was considered (rs2235498, rs2844455, rs9277756). That means 
they were not associated with ACPA-positive RA on their own. We further explored whether 
any interacting effects with ACPA-negative RA, and no such effects were observed within 
selected HLA region in this study. 
 
5.5   Conditional tests on HLA-DRB1 shared epitope (SE) alleles 
HLA-DRB1 shared epitope information was included in the model as a covariate, so that we 
were able to assess potential independent effects. Interaction effects from dominant model 
completely vanished after corrected for shared epitope alleles, and interacting amino acids 
from recessive and co-dominant models also decreased dramatically.  
In the GWAS material, no interacting SNPs remained in the dominant model after the 
inclusion of „any shared epitope‟ as a covariate. A total number of 22 amino acid positions 
were observed in the co-dominant model: HLA-DRB1 position -24, 11, 13, 33, 37, 96, 98, 
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104, 120, 180; HLA-DQA1 position 26, 47, 50, 53, 56, 76, 187, 215; HLA-DQB1 30, 55, 
140, 182. Besides, 12 out of these 22 amino acids were also observed in the recessive model. 
Similar results were found in the Immunochip material that none interacting SNPs remained 
in the dominant model. 12 amino acids were observed in the co-dominant model: HLA-
DRB1 position -24, 11, 13, 33, 96, 120, 180; HLA-DQA1 position 26, 47, 56, 76, 187, 
including 5 observed amino acid positions demonstrated in the recessive model (Table 2). 
Still, the highest attributable proportion appeared in HLA-DRB1*0401 (AP: 0.807, 95% 
CI: 0.621 - 0.993, p = 1.767×10-17), even if *0401 per se is defined as part of shared epitope 
in DRB1. All interacting markers outside SE were also associated with ACPA-positive RA. 
 
6 Discussion 
6.1   Main findings 
In this study, we confirmed the association between HLA regions and ACPA-positive RA. 
Genetic effects were observed in both ACPA-positive and ACPA-negative cases from the 
Immunochip material. The GWAS data showed similar patterns of association within the 
HLA region, but the genetic effects were comparatively weaker. The finding is consistent 
with previous association studies, in which HLA-DRB1, HLA-B, and HLA-DPB1 were 
found to explain most of the of the MHC associations with ACPA-positive RA, while HLA-
DRB1 and HLA-B explain associations with ACPA-negative RA.17,20, 32 
There are three main findings presented in this study. First, we demonstrated a strong 
additive interaction between amino acids in HLA proteins and smoking in ACPA-positive 
RA, but not in ACPA-negative RA. This also coincides with previous evidences that ACPA-
positive and ACPA-negative RA are distinct diseases with respective unique mechanisms. 
The SNPs demonstrating highest suggestive associations with ACPA-negative RA were found 
in chromosome 2 and 7, which is out of the scope of the current study.33 Second, different 
subgroups of HLA class II region showed diverse favor in genetic models. Most HLA-DR 
alleles could be detected by all three genetic models, and co-dominant model almost covers 
all the HLA-DR alleles. That means alleles in HLA-DR region primarily follow a co-
dominant model. On the contrary, dominant model could hardly detect HLA-DQ alleles, 
13 
 
which indicates a recessive tendency, as well as a higher tolerance for heterozygous variants 
in HLA-DQ region. These observed preferences in genetic models may provide us with 
insight in potential genetic mechanisms. Third, shared epitope alleles explain most of the 
interacting effects from heterozygous variants, while HLA class II alleles outside the shared 
epitope region still have independent interacting effects due to homozygous variants. 
Additionally, we found three SNPs showing effects with ACPA-positive RA only when 
considering interaction with smoking. Among those, rs9277756 is located in HLA-DPB2 
region; rs2844455 is an intron variant located in zinc finger domain, and may have function 
in 5‟-UTR. It is a novel finding that might give rise to the exploration of translational 
regulation in HLA class II region. 
Although the overall performances are similar in both materials, more markers were 
found to be associated with RA in the Immunochip data in each genetic model (Fig 2). This is 
no surprising because the marker selection in the Immunochip data is less random, based on 
earlier findings and hypothesis suggesting potential immune roles of regions, and with much 
higher density. 
 
6.2   Strengths and limitations 
The current study has several strengths. Almost all the results observed in the GWAS data are 
also detected in the Immunochip material, which indicates that the false positive findings in 
this study are limited. We imputed genotypes from a large reference panel, so that despite the 
missing alleles of potential importance in the original marker set, alleles in the imputed 
marker set can still be detected. This will increase the ability to identify true biological 
effects. The EIRA study covers pure Caucasians with European ancestry. Therefore, unlike 
other genome-wide studies, correction for population stratification is not necessary for our 
study. Approaches such as principle component analysis could cause problems like over-
adjustment, since principle components per se explain the genetic effects, and thus the true 
effects will be underestimated, especially in the Immunochip data where alleles are picked on 
a priori basis. The utilization of EIRA sample successfully avoids this contradictory situation. 
Besides, as a national-based study, EIRA has covered a wide range of geographical areas in 
Sweden, which allow us to generalize the findings to the Swedish population. Furthermore, 
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three genetic models were applied in parallel, which maximized the ability to detect 
underlying interacting effects. It also demonstrated genetic patterns of preferences in different 
genetic models as described above. Despite diverse methods and strategies that used in gene-
environment interaction studies, we used the deviation from additivity of effects (additive 
interaction). This measurement of additive scale reflects the biological interactions better than 
methods based on multiplicative scale, and with higher sensitivity (Fig 3-5). 
Several limitations have to be mentioned. There underlies a recall bias, since the smoking 
status was assessed after diagnosis, and this sort of bias could be differential among cases and 
controls. The dichotomized environmental exposure is rough compared to genetic exposures. 
We included only pure non-smokers as „never smokers‟, and all the rest were defined as „ever 
smokers‟. Nevertheless, we did not take into account any dosage, duration, or smoking 
patterns of „ever smokers‟. This misclassification might cause an underestimation of the 
effects caused by smoking, especially in the light of a previous study where a dose dependent 
effect of smoking was observed. 34  Similarly, even if serum ACPA was measured as 
continuous, it was stratified to a binary status. Previous studies suggest heterogeneity among 
ACPA-negative RA subjects due to lack of a specific test for ACPA-negative RA. For 
instance, ACPA-positive RA individuals fail to be detected in anti-CCP test will be included 
as ACPA-negative RA cases, and this can be a source of bias for tests regarding ACPA-
negative RA.32,35 If there were any interacting effects from ACPA-negative RA however did 
not show in this study, one possible explanation is that the heterogeneity among ACPA-
negative RA diluted the effects. Also, we cannot exclude the possibility of gene-gene 
interactions, since smoking habits might to some extent be genetically driven.36  
Preceding studies used formulas developed by Hosmer and Lemeshow to calculate a 
symmetrical confidence interval of AP. The excess risk for disease, however, is usually not 
symmetrical about the estimate. A rigid application of symmetrical AP would be problematic. 
For example, the higher bound of 95% confidence interval might exceed 1. Although this 
type of irrational results did not appear in the current study, we may still have a doubt about 
the potential bias when measuring confidence interval of AP.  
Shared epitope alleles were classified using 2-digit and 4-digit DRB1 classical alleles, as 
described above. Nevertheless, the imputed markers in our study are largely related with 
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shared epitope alleles, or even based on them, such as DRB1*0401. When we explored the 
independent risk conditional on SE, the true effects might be over-adjusted, which is a source 
of underestimation. Furthermore, we found the highest AP in DRB1*0401 after conditioned 
on SE, despite *0401 is within DRB1 SE region. This coincides with previously reported 
results that *0401 has the highest relative risk among SE allele groups.37 Alternatively, it 
might be due to the low resolution of „with any shared epitope‟ variable. That means we 
primarily found other alleles than *0401 when subjects were classified. One option to avoid 
over-adjustment is to stratify for shared epitope status; however it requires larger sample size. 
 
6.3   Interpretations and future thoughts 
It has been challenging to explain biological mechanisms of gene-environmental interacting 
effects on complex diseases. In this study, we applied exhausted biallelic markers of loci with 
high polymorphisms, aiming to accumulate evidences for potential functional links between 
smoking and HLA proteins. The current findings infer the role of T-cell responses in the 
initiation of RA.35 Given the functional elucidation of immunological tolerance at molecule 
level, further studies can be focused on how these loci trigger T-cell activation differently in 
the present or absent of smoking. Alternatively, a deeper understanding of functional 
mechanisms of interacting effects with smoking might be achieved in the light of information 
on secondary or higher structure of HLA proteins. 
 
6.4   Public health implications 
To date, patients with RA still suffer a higher mortality rate than the general population, and it 
is related with a great underlying social loss.38 Approximately one third of RA patients cannot 
continue their work within two years of the disease onset. What‟s more, life expectancy has 
been reduced by 7 years in men and 3 years in women, as a result of systematic complications 
and RA itself.1 Conventional therapies aim at clinical remission, however is lacking in 
molecular remission. Sustained remission would be expected to maintain through novel 
therapeutics that may provide the promise of higher therapeutic responses and the rebuilt of 
auto-immunologic tolerance.39  
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This work is a combination of molecular and public health data regarding an 
investigation of a complex disease which have the potential to find important mechanisms 
that may offer the perspective of the formation of future prevention strategies. Genetic 
screening for risk loci among general population is becoming feasible, achieved by the 
introduction of high-throughput sequencing. As genetic risk and lifestyle information 
integrated, a revolution of disease prevention is predictable. Even if a genetic background 
with increased risk is doomed, one can still get personalized advice such as smoking 
cessation, both before and at the early stage of disease onset. 
 
7 Conclusion  
This study is consistent with previous results that smoking interacting with genotypic variants 
in HLA proteins in relation to the risk of ACPA-positive RA, and the interacting effects 
remain after controlling for DRB1 shared epitope alleles. We narrowed down the scope to 
HLA class II region, and further discovered a total number of 48 amino acid positions within 
HLA-DRB1, DQA1, and DQB1 showing interactions with smoking, 22 remained after 
correction for SE. We did not observe any evidence for gene-smoking interaction with regard 
to ACPA-negative RA. The study provides evidence for gene-smoking interaction 
mechanisms in ACPA-positive RA, so as to bridge the gap from understanding the disease at 
the nucleotide level to a higher functional level. 
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Table 1. Characteristic description of rheumatoid arthritis statue stratified by ACPA 
  
 GWAS data Immunochip data 
 
RA  ACPA-positive  
cases n (%) 
N=1,101 
RA  ACPA-negative  
cases n (%) 
N=714 
RA controls n (%) 
N=1,079 
RA  ACPA-positive  
cases n (%) 
N=1,590 
RA  ACPA-negative  
cases n (%) 
N=891 
RA controls n (%) 
N=1,856 
EIRA       
      EIRA I 1,067 (96.9) 699 (97.9) 1,067 (98.9) 1,074 (67.5) 634 (71.2) 971 (52.3) 
      EIRA II 34 (3.1) 15 (2.1) 0 516 (32.5) 257 (28.8) 885 (47.7) 
      NA 0 0 12 (1.1) 0 0 0 
Sex       
      Male 318 (28.9) 212 (29.7) 299 (27.7) 1,119 (70.4) 631 (70.8) 1,370 (73.8) 
      Female 783 (71.1) 502 (70.3) 768 (71.2) 471 (29.6) 260 (29.2) 486 (26.2) 
      NA 0 0 12 (1.1) 0 0 0 
Age, mean± sd (years) 51.3 ± 12.0 51.5 ± 13.1 52.9 ± 11.6 51.2 ± 12.3 52.9 ± 11.7 54.2 ± 11.1 
Living area       
      Stockholm 622 (56.5) 377 (52.8) 581 (53.8) 882 (55.5) 480 (53.9) 1016 (54.7) 
      Outside Stockholm 477 (43.3) 337 (47.2) 485 (44.9) 708 (44.5) 411 (46.1) 840 (45.3) 
      NA 2 (0.2) 0 13 (1.2) 0 0 0 
Cigarette smoking       
      Never smokers 279 (25.3) 276 (38.7) 392 (36.3) 430 (27.1) 340 (38.2) 746 (40.2) 
      Ever smokers 821 (74.6) 434 (60.8) 670 (62.1) 1,064 (66.9) 493 (55.3) 994 (53.6) 
      NA 1 (0.1) 4 (0.5) 17 (1.6) 96 (6.0) 58 (6.5) 116 (6.2) 
Shared epitope       
     Any shared epitope 918 (83.4) 393 (55.0) 416 (38.5) 1,236 (77.7) 430 (48.2) 890 (48.0) 
     None shared epitope 159 (14.4) 314 (44.0) 427 (39.6) 220 (13.9) 374 (42.0) 758 (40.8) 
     NA 24 (2.2) 7 (1.0) 236 (21.9) 134 (8.4) 87 (9.8) 208 (11.2) 
18 
 
 
Table 2. Additive interaction comparison across materials  
HLA 
region 
Position 
Additive interaction in GWAS data 
Additive interaction in Immunochip 
Data 
Interaction 
effect only 
Condition on SE 
Interaction 
effect only 
Condition on SE 
DRB1 -25 Yes  Yes  
 -24 Yes Yes Yes Yes 
 -16 Yes  Yes  
 10 Yes  Yes  
 11 Yes Yes Yes Yes 
 12 Yes  Yes  
 13 Yes Yes Yes Yes 
 32 Yes  Yes  
 33 Yes Yes Yes  
 37 Yes Yes Yes  
 47 Yes  Yes  
 67   Yes  
 70 Yes  Yes  
 73   Yes  
 74 Yes  Yes  
 96 Yes Yes Yes Yes 
 98 Yes Yes   
 104 Yes Yes   
 120 Yes Yes Yes Yes 
 149 Yes  Yes  
 180 Yes Yes Yes Yes 
 233 Yes  Yes  
DQA1 26 Yes Yes Yes Yes 
 34 Yes  Yes  
 40 Yes  Yes  
 47 Yes Yes Yes Yes 
 50 Yes Yes Yes  
 51 Yes  Yes  
 53 Yes Yes Yes  
 56 Yes Yes Yes Yes 
 76 Yes Yes Yes Yes 
 175 Yes    
 187 Yes Yes Yes Yes 
 215 Yes Yes   
DQB1 -10 Yes  Yes  
 28 Yes  Yes  
 30 Yes Yes Yes  
 37 Yes  Yes  
 46 Yes  Yes  
 47 Yes  Yes  
 52 Yes  Yes  
 55 Yes Yes Yes  
 66   Yes  
 67   Yes  
 71 Yes  Yes  
 74 Yes  Yes  
 140 Yes Yes   
 182 Yes Yes   
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Fig 1. HLA and immune recognition.40 
 
 
 
 
 
 
(a) HLA structure. (b) HLA class II molecule structure. (c) The role of HLA class II 
molecule in T-cell activation. 
  
(a) 
(b) (c) 
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Fig 2. Association between SNPs within HLA and rheumatoid arthritis.  
 
 
 
 
 
(a) GWAS data association tests for ACPA-positive and (b) APCA-negative RA.  
(c) Immunochip data association tests for ACPA-positive and (d) ACPA-negative RA. 
  
HLA-DRB1 position 11 
rs9268861 
DRB1 position 74 
DRB1 position 13 
(a) 
(b) 
(c) 
(d) 
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Fig 3. Multiplicative interaction between SNPs in HLA and smoking in relation to 
APCA+ rheumatoid arthritis, adjusted for sex, age, living area.  
 
(a) GWAS data interacting effects in multiplicative scale. (b) Immunochip data interacting 
effects in multiplicative scale. 
 
  
(a) 
(b) 
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Fig 4. GWAS material additive interaction between SNPs in HLA and smoking in 
relation to ACPA-positive rheumatoid arthritis in additive model, adjusted for sex, age, 
living area. 
 
 
(a) Interacting effects. (b) Interacting effects after controlling for SE alleles. 
  
DRB1*0401 
DRB1 position 11 
DRB1*0401 
DRB1 position 11 
(a) 
(b) 
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Fig 5. Immunochip material additive interaction between SNPs in HLA and smoking in 
relation to ACPA-positive rheumatoid arthritis in additive model, adjusted for sex, age, 
living area. 
 
 
(a) Interacting effects. (b) Interacting effects after controlling for SE alleles.  
rs9268557 
DRB1 position 74 
DRB1*0401 
rs9784858 
(a) 
(b) 
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Appendix Table. Additive interacting effects from co-dominant model in GWAS material 
and Immunochip material. For each marker showing interacting effects with smoking in 
relation to ACPA-positive RA unconditional for shared epitope alleles, we listed the 
corresponding association test statistics. Allele frequency rates among cases and controls are also 
listed. Loci with high polymorphisms have been exhaustively grouped. Results from association 
test and interacting test in GWAS material are presented in Appendix Table a; results from 
association test and interacting test in Immunochip material are presented in Appendix Table b. 
Appendix Table a. 
SNP 
χ
2 
log10(p) 
Allele Frequency 
AP (95%CI) log10(p) 
Cases Controls 
rs2844455 19.7 -5.05 0.2184 0.1654 0.664 (0.404-0.924) -6.24 
rs3117099 75.5 -17.44 0.1417 0.2456 0.462 (0.263-0.660) -5.29 
rs9268528 143.9 -32.43 0.5409 0.3601 0.572 (0.402-0.743) -10.29 
rs9268542 140.2 -31.61 0.5409 0.3624 0.578 (0.408-0.747) -10.67 
rs9268543 247.0 -54.92 0.4201 0.1997 0.664 (0.450-0.877) -8.97 
rs9268556 140.2 -31.61 0.5409 0.3624 0.578 (0.408-0.747) -10.67 
rs2395163 231.4 -51.53 0.4432 0.2257 0.579 (0.334-0.823) -5.46 
rs9268557 176.9 -39.65 0.3215 0.5204 0.510 (0.347-0.672) -9.11 
rs2187818 151.1 -34.01 0.5368 0.3517 0.511 (0.314-0.708) -6.44 
rs9268585 152.0 -34.21 0.5354 0.3499 0.515 (0.32-0.711) -6.61 
rs9268589 148.2 -33.36 0.5359 0.3526 0.516 (0.324-0.710) -6.80 
rs9268606 148.2 -33.36 0.5359 0.3526 0.516 (0.324-0.710) -6.80 
rs7773756 148.2 -33.36 0.5359 0.3526 0.516 (0.324-0.710) -6.80 
rs9268615 146.7 -33.03 0.5436 0.3610 0.506 (0.313-0.70) -6.53 
rs14004 153.2 -34.46 0.5395 0.3531 0.515 (0.320-0.710) -6.63 
rs9268645 147.4 -33.20 0.5354 0.3526 0.515 (0.321-0.708) -6.71 
rs9268657 151.3 -34.05 0.5350 0.3499 0.513 (0.317-0.710) -6.51 
rs7192 167.9 -37.67 0.2675 0.4560 0.452 (0.283-0.620) -6.82 
rs7195 167.9 -37.67 0.2675 0.4560 0.452 (0.283-0.620) -6.82 
rs2213586 167.9 -37.67 0.2675 0.4560 0.452 (0.283-0.620) -6.82 
rs2213585 168.8 -37.86 0.2670 0.4560 0.453 (0.284-0.621) -6.88 
rs2227139 168.8 -37.86 0.2670 0.4560 0.453 (0.284-0.621) -6.88 
rs3763327 168.8 -37.86 0.2670 0.4560 0.453 (0.284-0.621) -6.88 
rs7754768 165.0 -37.03 0.2761 0.4639 0.480 (0.317-0.643) -8.08 
rs9268832 167.5 -37.58 0.2702 0.4588 0.501 (0.341-0.660) -9.10 
rs9268853 198.1 -44.26 0.5041 0.2952 0.537 (0.328-0.745) -6.36 
rs9268923 197.3 -44.08 0.5036 0.2952 0.543 (0.338-0.749) -6.67 
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rs2395185 197.3 -44.08 0.5036 0.2952 0.543 (0.338-0.749) -6.67 
rs9268969 197.3 -44.08 0.5036 0.2952 0.543 (0.338-0.749) -6.67 
rs9368726 197.3 -44.08 0.5036 0.2952 0.543 (0.338-0.749) -6.67 
rs9405108 197.3 -44.08 0.5036 0.2952 0.543 (0.338-0.749) -6.67 
rs1964995 258.7 -57.48 0.3392 0.5820 0.515 (0.345-0.684) -8.54 
AA_DRB1_233_32656004_R 165.0 -37.04 0.1948 0.3698 0.464 (0.298-0.630) -7.35 
AA_DRB1_233_32656004_T 190.2 -42.53 0.2216 0.4161 0.495 (0.340-0.650) -9.44 
SNP_DRB1_32656004 165.0 -37.04 0.1948 0.3698 0.464 (0.298-0.630) -7.35 
SNP_DRB1_32656559 316.8 -70.14 0.5799 0.3119 0.557 (0.362-0.752) -7.67 
SNP_DRB1_32657334 260.7 -57.91 0.3383 0.5820 0.512 (0.341-0.683) -8.36 
AA_DRB1_180_32657338_L 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
AA_DRB1_180_32657338_V 251.0 -55.80 0.4623 0.2335 0.630 (0.418-0.843) -8.23 
SNP_DRB1_32657339 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
SNP_DRB1_32657430 199.2 -44.50 0.2225 0.4222 0.500 (0.347-0.652) -9.90 
AA_DRB1_149_32657431_H 199.2 -44.50 0.2225 0.4222 0.500 (0.347-0.652) -9.90 
AA_DRB1_149_32657431_Q 199.2 -44.50 0.2225 0.4222 0.500 (0.347-0.652) -9.90 
SNP_DRB1_32657475 199.2 -44.50 0.2225 0.4222 0.500 (0.347-0.652) -9.90 
AA_DRB1_120_32657518_N 320.1 -70.85 0.4609 0.2053 0.674 (0.476-0.872) -10.59 
AA_DRB1_120_32657518_S 320.1 -70.85 0.4609 0.2053 0.674 (0.476-0.872) -10.59 
SNP_DRB1_32657518 320.1 -70.85 0.4609 0.2053 0.674 (0.476-0.872) -10.59 
SNP_DRB1_32657526 172.4 -38.67 0.2439 0.4319 0.466 (0.302-0.63) -7.56 
AA_DRB1_104_32657566_A 197.1 -44.04 0.5000 0.2919 0.550 (0.348-0.754) -6.98 
AA_DRB1_104_32657566_S 197.1 -44.04 0.5000 0.2919 0.550 (0.348-0.754) -6.98 
SNP_DRB1_32657567 197.1 -44.04 0.5000 0.2919 0.550 (0.348-0.754) -6.98 
AA_DRB1_98_32657584_E 197.1 -44.04 0.5000 0.2919 0.550 (0.348-0.754) -6.98 
AA_DRB1_98_32657584_K 197.1 -44.04 0.5000 0.2919 0.550 (0.348-0.754) -6.98 
SNP_DRB1_32657585 197.1 -44.04 0.5000 0.2919 0.550 (0.348-0.754) -6.98 
AA_DRB1_96_32657590_H 252.2 -56.06 0.2829 0.5185 0.518 (0.36-0.676) -9.85 
AA_DRB1_96_32657590_HE 195.8 -43.76 0.5767 0.3652 0.576 (0.408-0.743) -10.83 
AA_DRB1_96_32657590_HQ 316.8 -70.14 0.5799 0.3119 0.557 (0.362-0.752) -7.67 
AA_DRB1_96_32657590_Hx 252.2 -56.06 0.2829 0.5185 0.518 (0.36-0.676) -9.85 
AA_DRB1_96_32657590_QY 195.8 -43.76 0.5767 0.3652 0.576 (0.408-0.743) -10.83 
AA_DRB1_96_32657590_Y 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
AA_DRB1_96_32657590_YE 316.8 -70.14 0.5799 0.3119 0.557 (0.362-0.752) -7.67 
AA_DRB1_96_32657590_Yx 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
SNP_DRB1_32657591_A 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
SNP_DRB1_32657591_G 316.8 -70.14 0.5799 0.3119 0.557 (0.362-0.752) -7.67 
AA_DRB1_74_32659926_A 90.2 -20.67 0.1812 0.3044 0.448 (0.263-0.632) -5.71 
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AA_DRB1_74_32659926_AE 77.8 -17.95 0.1512 0.259 0.509 (0.318-0.701) -6.71 
SNP_DRB1_32659926_G 90.2 -20.67 0.1812 0.3044 0.448 (0.263-0.632) -5.71 
SNP_DRB1_32659927 77.8 -17.95 0.1512 0.2590 0.509 (0.318-0.701) -6.71 
SNP_DRB1_32659937 161.4 -36.25 0.1889 0.3605 0.450 (0.294-0.606) -7.78 
AA_DRB1_70_32659938_D 161.4 -36.25 0.1889 0.3605 0.450 (0.294-0.606) -7.78 
AA_DRB1_70_32659938_Q 150.4 -33.86 0.2352 0.4087 0.389 (0.217-0.561) -5.04 
SNP_DRB1_32659939 161.4 -36.25 0.1889 0.3605 0.450 (0.294-0.606) -7.78 
AA_DRB1_47_32660007 198.3 -44.32 0.2906 0.4991 0.429 (0.248-0.610) -5.46 
SNP_DRB1_32660007 198.3 -44.32 0.2906 0.4991 0.429 (0.248-0.610) -5.46 
AA_DRB1_37_32660037_NF 187.7 -42.01 0.1998 0.3888 0.463 (0.300-0.627) -7.58 
AA_DRB1_37_32660037_NL 131.8 -29.78 0.1599 0.3068 0.493 (0.319-0.667) -7.54 
AA_DRB1_37_32660037_NS 115.9 -26.30 0.3996 0.5626 0.488 (0.311-0.666) -7.20 
AA_DRB1_37_32660037_SY 189.2 -42.33 0.2162 0.4092 0.458 (0.294-0.623) -7.31 
AA_DRB1_37_32660037_Y 202.8 -45.29 0.5277 0.3146 0.582 (0.398-0.766) -9.22 
AA_DRB1_37_32660037_YF 121.5 -27.53 0.4160 0.5829 0.516 (0.346-0.686) -8.60 
AA_DRB1_37_32660037_YL 193.2 -43.19 0.5441 0.3350 0.532 (0.334-0.729) -6.87 
SNP_DRB1_32660038_A 131.8 -29.78 0.1599 0.3068 0.493 (0.319-0.667) -7.54 
HLA_DRB1_04 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
HLA_DRB1_0401 197.5 -44.15 0.3088 0.1321 0.814 (0.63-0.998) -17.44 
SNP_DRB1_32660045 245.8 -54.68 0.3174 0.5528 0.500 (0.331-0.669) -8.19 
AA_DRB1_33_32660049 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
SNP_DRB1_32660050 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
AA_DRB1_32_32660052 123.2 -27.90 0.1771 0.3225 0.462 (0.276-0.648) -5.94 
SNP_DRB1_32660053 123.2 -27.90 0.1771 0.3225 0.462 (0.276-0.648) -5.94 
SNP_DRB1_32660090 217.0 -48.39 0.5213 0.3017 0.560 (0.367-0.753) -7.90 
AA_DRB1_13_32660109_H 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
AA_DRB1_13_32660109_HF 336.5 -74.42 0.6153 0.3378 0.568 (0.391-0.744) -9.55 
AA_DRB1_13_32660109_HG 220.0 -49.04 0.4805 0.2632 0.582 (0.368-0.796) -7.01 
AA_DRB1_13_32660109_HY 203.2 -45.37 0.4855 0.2757 0.575 (0.372-0.778) -7.55 
AA_DRB1_13_32660109_RH 175.7 -39.37 0.5554 0.3554 0.547 (0.366-0.729) -8.46 
AA_DRB1_13_32660109_SFG 119.9 -27.17 0.3987 0.5644 0.479 (0.297-0.662) -6.60 
AA_DRB1_13_32660109_SG 198.2 -44.28 0.223 0.4222 0.499 (0.347-0.652) -9.87 
AA_DRB1_13_32660109_SR 211.9 -47.28 0.2979 0.5144 0.461 (0.284-0.637) -6.52 
AA_DRB1_13_32660109_SRF 148.4 -33.41 0.5263 0.3434 0.489 (0.278-0.699) -5.28 
AA_DRB1_13_32660109_SRG 259.7 -57.69 0.3388 0.5820 0.511 (0.340-0.682) -8.31 
AA_DRB1_13_32660109_SRY 275.3 -61.09 0.3438 0.5945 0.495 (0.313-0.677) -7.000 
AA_DRB1_13_32660109_SY 210.5 -46.97 0.2280 0.4347 0.482 (0.325-0.639) -8.75 
AA_DRB1_13_32660109_SYF 130.8 -29.57 0.4037 0.5769 0.480 (0.294-0.666) -6.38 
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AA_DRB1_13_32660109_SYG 251.1 -55.81 0.2688 0.5023 0.528 (0.377-0.680) -11.11 
SNP_DRB1_32660109_GC 259.7 -57.69 0.3388 0.5820 0.511 (0.340-0.682) -8.31 
SNP_DRB1_32660109_T 203.2 -45.37 0.4855 0.2757 0.575 (0.372-0.778) -7.55 
SNP_DRB1_32660110_A 130.8 -29.57 0.4037 0.5769 0.480 (0.294-0.666) -6.38 
SNP_DRB1_32660110_AC 175.7 -39.37 0.5554 0.3554 0.547 (0.366-0.729) -8.46 
SNP_DRB1_32660110_AT 220.0 -49.04 0.4805 0.2632 0.582 (0.368-0.796) -7.01 
SNP_DRB1_32660110_G 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
SNP_DRB1_32660111 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
AA_DRB1_12_32660112 198.2 -44.28 0.2230 0.4222 0.499 (0.347-0.652) -9.87 
SNP_DRB1_32660112 198.2 -44.28 0.2230 0.4222 0.499 (0.347-0.652) -9.87 
AA_DRB1_11_32660115_PV 195.8 -43.76 0.5767 0.3652 0.576 (0.408-0.743) -10.83 
AA_DRB1_11_32660115_S 198.2 -44.28 0.2230 0.4222 0.499 (0.347-0.652) -9.87 
AA_DRB1_11_32660115_SD 196.8 -43.99 0.2375 0.4384 0.492 (0.336-0.648) -9.22 
AA_DRB1_11_32660115_SG 251.1 -55.81 0.2688 0.5023 0.528 (0.377-0.680) -11.11 
AA_DRB1_11_32660115_SGD 251.2 -55.84 0.2834 0.5185 0.517 (0.358-0.675) -9.79 
AA_DRB1_11_32660115_SGL 192.2 -42.98 0.5913 0.3814 0.584 (0.426-0.743) -12.30 
AA_DRB1_11_32660115_SL 135.8 -30.66 0.3629 0.5385 0.510 (0.345-0.676) -8.81 
AA_DRB1_11_32660115_SLD 137.7 -31.07 0.3774 0.5547 0.511 (0.342-0.680) -8.54 
AA_DRB1_11_32660115_SP 259.7 -57.69 0.3388 0.5820 0.511 (0.340-0.682) -8.31 
AA_DRB1_11_32660115_SPD 262.2 -58.24 0.3533 0.5982 0.518 (0.344-0.691) -8.29 
AA_DRB1_11_32660115_SPG 336.5 -74.42 0.6153 0.3378 0.568 (0.391-0.744) -9.55 
AA_DRB1_11_32660115_SPL 217.0 -48.39 0.5213 0.3017 0.560 (0.367-0.753) -7.90 
AA_DRB1_11_32660115_V 320.1 -70.85 0.4609 0.2053 0.674 (0.476-0.872) -10.59 
AA_DRB1_11_32660115_VD 309.1 -68.47 0.4755 0.2215 0.669 (0.483-0.854) -11.75 
AA_DRB1_11_32660115_VG 223.0 -49.71 0.5068 0.2854 0.582 (0.389-0.775) -8.48 
AA_DRB1_11_32660115_VL 341.8 -75.59 0.6008 0.3216 0.565 (0.379-0.751) -8.55 
SNP_DRB1_32660115_A 341.8 -75.59 0.6008 0.3216 0.565 (0.379-0.751) -8.55 
SNP_DRB1_32660115_G 259.7 -57.69 0.3388 0.5820 0.511 (0.340-0.682) -8.31 
SNP_DRB1_32660115_GC 336.5 -74.42 0.6153 0.3378 0.568 (0.391-0.744) -9.55 
SNP_DRB1_32660115_GT 262.2 -58.24 0.3533 0.5982 0.518 (0.344-0.691) -8.29 
SNP_DRB1_32660116_A 198.2 -44.28 0.2230 0.4222 0.499 (0.347-0.652) -9.87 
SNP_DRB1_32660116_C 217.0 -48.39 0.5213 0.3017 0.560 (0.367-0.753) -7.90 
SNP_DRB1_32660117 198.2 -44.28 0.2230 0.4222 0.499 (0.347-0.652) -9.87 
AA_DRB1_10_32660118_Q 171.6 -38.47 0.2443 0.4319 0.466 (0.301-0.630) -7.53 
AA_DRB1_10_32660118_Y 198.2 -44.28 0.2230 0.4222 0.499 (0.347-0.652) -9.87 
SNP_DRB1_32660119_A 198.2 -44.28 0.2230 0.4222 0.499 (0.347-0.652) -9.87 
SNP_DRB1_32660119_G 171.6 -38.47 0.2443 0.4319 0.466 (0.301-0.630) -7.53 
SNP_DRB1_32665401 152.1 -34.21 0.2216 0.3939 0.433 (0.255-0.612) -5.73 
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AA_DRB1_-16_32665457_A 171.6 -38.47 0.2443 0.4319 0.466 (0.301-0.630) -7.53 
AA_DRB1_-16_32665457_V 144.3 -32.52 0.2166 0.3832 0.422 (0.241-0.602) -5.32 
SNP_DRB1_32665457 171.6 -38.47 0.2443 0.4319 0.466 (0.301-0.630) -7.53 
AA_DRB1_-24_32665481_F 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
AA_DRB1_-24_32665481_L 236.3 -52.61 0.4673 0.2442 0.630 (0.419-0.842) -8.31 
SNP_DRB1_32665482 298.9 -66.24 0.4396 0.1956 0.679 (0.474-0.885) -10.04 
AA_DRB1_-25_32665484_K 171.6 -38.47 0.2443 0.4319 0.466 (0.301-0.630) -7.53 
AA_DRB1_-25_32665484_R 144.3 -32.52 0.2166 0.3832 0.422 (0.241-0.602) -5.32 
SNP_DRB1_32665484 171.6 -38.47 0.2443 0.4319 0.466 (0.301-0.630) -7.53 
rs477515 196.5 -43.92 0.4900 0.2831 0.582 (0.385-0.780) -8.12 
rs2858867 91.0 -20.83 0.2330 0.3652 0.419 (0.237-0.601) -5.19 
rs482044 102.4 -23.35 0.5436 0.3906 0.496 (0.308-0.684) -6.63 
rs660895 238.7 -53.11 0.4637 0.2400 0.631 (0.425-0.836) -8.72 
rs522308 195.0 -43.58 0.4886 0.2827 0.577 (0.378-0.777) -7.84 
rs521539 238.7 -53.11 0.4637 0.2400 0.631 (0.425-0.836) -8.72 
rs3104413 301.2 -66.73 0.4401 0.1951 0.680 (0.474-0.885) -10.06 
rs6931277 301.2 -66.73 0.4401 0.1951 0.680 (0.474-0.885) -10.06 
rs9271488 192.4 -43.03 0.5005 0.2947 0.552 (0.352-0.752) -7.17 
rs9271588 226.0 -50.36 0.3233 0.5491 0.492 (0.321-0.663) -7.78 
rs3104389 192.4 -43.03 0.5005 0.2947 0.552 (0.352-0.752) -7.17 
rs9272105 114.6 -26.01 0.3828 0.5445 0.481 (0.306-0.656) -7.11 
SNP_DQA1_32713273 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
HLA_DQA1_03 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
HLA_DQA1_0301 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
SNP_DQA1_32717072 123.0 -27.85 0.5027 0.3369 0.521 (0.324-0.717) -6.67 
SNP_DQA1_32717084 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32717108 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
SNP_DQA1_32717120 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
AA_DQA1_26_32717128 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
SNP_DQA1_32717128 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
SNP_DQA1_32717147 150.2 -33.82 0.5236 0.3397 0.508 (0.308-0.708) -6.19 
SNP_DQA1_32717151 230.1 -51.24 0.3302 0.5584 0.494 (0.322-0.667) -7.69 
AA_DQA1_34_32717152 230.1 -51.24 0.3302 0.5584 0.494 (0.322-0.667) -7.69 
SNP_DQA1_32717159 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32717190_C 96.3 -22.00 0.2121 0.3452 0.493 (0.322-0.664) -7.81 
AA_DQA1_47_32717191_Q 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
AA_DQA1_47_32717191_RC 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
AA_DQA1_47_32717191_RQ 96.3 -22.00 0.2121 0.3452 0.493 (0.322-0.664) -7.81 
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SNP_DQA1_32717191 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32717199 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
AA_DQA1_50_32717200_L 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32717205 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
AA_DQA1_53_32717209_R 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32717209 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32717217_A 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
SNP_DQA1_32717217_x 96.3 -22.00 0.2121 0.3452 0.493 (0.322-0.664) -7.81 
AA_DQA1_56_32717218_R 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
AA_DQA1_56_32717218_x 96.3 -22.00 0.2121 0.3452 0.493 (0.322-0.664) -7.81 
SNP_DQA1_32717219_A 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
SNP_DQA1_32717219_x 96.3 -22.00 0.2121 0.3452 0.493 (0.322-0.664) -7.81 
SNP_DQA1_32717277_C 96.3 -22.00 0.2121 0.3452 0.493 (0.322-0.664) -7.81 
SNP_DQA1_32717277_G 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
AA_DQA1_76_32717278_L 96.3 -22.00 0.2121 0.3452 0.493 (0.322-0.664) -7.81 
AA_DQA1_76_32717278_V 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
SNP_DQA1_32717833 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32717986 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32717987_G 150.2 -33.82 0.5236 0.3397 0.508 (0.308-0.708) -6.19 
AA_DQA1_175_32717988_E 150.2 -33.82 0.5236 0.3397 0.508 (0.308-0.708) -6.19 
AA_DQA1_175_32717988_QK 150.2 -33.82 0.5236 0.3397 0.508 (0.308-0.708) -6.19 
SNP_DQA1_32718379 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
AA_DQA1_187_32718380_A 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
AA_DQA1_187_32718380_T 280.6 -62.25 0.4541 0.2146 0.672 (0.484-0.861) -11.56 
SNP_DQA1_32718381 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32718456 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32718459 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
AA_DQA1_215_32718464_F 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
AA_DQA1_215_32718464_L 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQA1_32718465 191.6 -42.85 0.5000 0.2947 0.551 (0.351-0.752) -7.14 
SNP_DQB1_32737124 141.1 -31.81 0.5577 0.3781 0.531 (0.355-0.707) -8.45 
AA_DQB1_182_32737742_N 141.1 -31.81 0.5577 0.3781 0.531 (0.355-0.707) -8.45 
AA_DQB1_182_32737742_S 142.5 -32.12 0.5590 0.3786 0.537 (0.363-0.712) -8.82 
SNP_DQB1_32737742 141.1 -31.81 0.5577 0.3781 0.531 (0.355-0.707) -8.45 
SNP_DQB1_32737837 195.3 -43.65 0.2593 0.4625 0.475 (0.315-0.635) -8.21 
AA_DQB1_140_32737868_A 142.5 -32.12 0.5590 0.3786 0.537 (0.363-0.712) -8.82 
AA_DQB1_140_32737868_T 141.1 -31.81 0.5577 0.3781 0.531 (0.355-0.707) -8.45 
SNP_DQB1_32737869 141.1 -31.81 0.5577 0.3781 0.531 (0.355-0.707) -8.45 
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SNP_DQB1_32737933 141.1 -31.81 0.5577 0.3781 0.531 (0.355-0.707) -8.45 
HLA_DQB1_03 174.8 -39.19 0.5336 0.3350 0.561 (0.38-0.743) -8.89 
AA_DQB1_55_32740672_P 174.1 -39.02 0.5332 0.3350 0.559 (0.377-0.741) -8.73 
SNP_DQB1_32740672_G 174.1 -39.02 0.5332 0.3350 0.559 (0.377-0.741) -8.73 
SNP_DQB1_32740722 174.1 -39.02 0.5332 0.3350 0.559 (0.377-0.741) -8.73 
AA_DQB1_30_32740747_Y 81.8 -18.82 0.3347 0.4690 0.522 (0.356-0.688) -9.19 
SNP_DQB1_32740748_A 81.8 -18.82 0.3347 0.4690 0.522 (0.356-0.688) -9.19 
SNP_DQB1_32742296_C 161.5 -36.27 0.1730 0.3411 0.500 (0.346-0.654) -9.67 
rs9275141 113.3 -25.74 0.4024 0.5635 0.436 (0.246-0.626) -5.16 
rs4642516 113.3 -25.74 0.4024 0.5635 0.436 (0.246-0.626) -5.16 
rs9275224 208.3 -46.48 0.2761 0.4884 0.454 (0.285-0.622) -6.87 
rs2858324 182.7 -40.9 0.2448 0.4388 0.436 (0.268-0.604) -6.47 
rs5000634 143.1 -32.25 0.5609 0.3800 0.500 (0.315-0.685) -6.93 
rs6457617 209.1 -46.66 0.2816 0.4949 0.457 (0.288-0.626) -6.95 
rs6457620 209.1 -46.66 0.2816 0.4949 0.457 (0.288-0.626) -6.95 
rs7745040 143.1 -32.25 0.5609 0.3800 0.500 (0.315-0.685) -6.93 
rs2647012 181.9 -40.72 0.2448 0.4384 0.440 (0.273-0.606) -6.65 
rs1612904 161.5 -36.27 0.2334 0.4133 0.441 (0.274-0.607) -6.67 
rs2856717 178.7 -40.04 0.2443 0.4361 0.435 (0.267-0.603) -6.43 
rs9275516 206.1 -46.02 0.2688 0.4791 0.456 (0.288-0.624) -7.00 
rs6932517 206.0 -46.00 0.2693 0.4796 0.448 (0.278-0.617) -6.65 
rs9275596 161.5 -36.27 0.2334 0.4133 0.429 (0.261-0.598) -6.22 
rs3819721 75.9 -17.52 0.3915 0.2674 0.535 (0.301-0.768) -5.14 
rs9357155 37.7 -9.08 0.2134 0.1423 0.693 (0.39-0.995) -5.14 
rs9277756 16.2 -4.25 0.2148 0.1668 0.653 (0.365-0.941) -5.05 
rs2235498 8.4 -2.42 0.2003 0.1664 0.706 (0.451-0.962) -7.23 
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Appendix Table b. 
SNP χ
2
 log10(p) 
Allele Frequency 
AP (95%CI) log10(p) 
Cases Controls 
rs261945 22.1 -5.58 0.4965 0.4399 0.444 (0.258-0.629) -5.57 
rs1264423 30.7 -7.53 0.3877 0.4539 0.447 (0.265-0.629) -5.81 
rs1264419 31.0 -7.60 0.3874 0.4539 0.443 (0.261-0.625) -5.72 
rs2844503 44.9 -10.68 0.5324 0.4515 0.452 (0.271-0.633) -6.01 
rs412657 95.4 -21.81 0.2717 0.3828 0.390 (0.232-0.549) -5.87 
rs6936204 114.5 -26.00 0.2503 0.3704 0.380 (0.215-0.544) -5.21 
rs3130320 129.0 -29.16 0.2610 0.3901 0.390 (0.235-0.545) -6.10 
rs3115569 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs9268055 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3115563 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3132928 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3096681 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3132931 97.3 -22.24 0.1462 0.2411 0.448 (0.282-0.615) -6.91 
rs3115560 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3096673 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3096674 97.3 -22.24 0.1462 0.2411 0.448 (0.282-0.615) -6.91 
rs3132945 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3096677 96.8 -22.12 0.1463 0.241 0.449 (0.283-0.615) -6.94 
rs3115557 97.3 -22.24 0.1462 0.2411 0.448 (0.282-0.615) -6.91 
rs1559873 97.8 -22.34 0.1487 0.2466 0.441 (0.273-0.608) -6.59 
rs1559874 96.0 -21.93 0.1469 0.2411 0.450 (0.283-0.616) -6.94 
rs3130340 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3115553 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs9268125 99.7 -22.74 0.1465 0.2427 0.453 (0.292-0.615) -7.43 
rs9268131 97.3 -22.24 0.1462 0.2411 0.448 (0.282-0.615) -6.91 
rs9268135 97.3 -22.24 0.1462 0.2411 0.448 (0.282-0.615) -6.91 
rs9268137 97.3 -22.24 0.1462 0.2411 0.448 (0.282-0.615) -6.91 
rs7751896 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs6935269 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs3749966 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs7750783 100.4 -22.91 0.1466 0.2433 0.452 (0.292-0.612) -7.54 
rs6909427 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs7775332 98.8 -22.55 0.1535 0.2505 0.442 (0.281-0.603) -7.14 
rs7742654 91.8 -21.02 0.1528 0.2460 0.450 (0.288-0.612) -7.25 
rs3864299 92.5 -21.17 0.1525 0.2460 0.451 (0.288-0.613) -7.28 
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rs3864300 91.8 -21.02 0.1528 0.2460 0.450 (0.288-0.612) -7.25 
rs9268165 91.8 -21.02 0.1528 0.2460 0.450 (0.288-0.612) -7.25 
rs9268166 91.8 -21.02 0.1528 0.2460 0.450 (0.288-0.612) -7.25 
rs9268167 98.6 -22.51 0.1538 0.2508 0.441 (0.279-0.602) -7.07 
rs6457536 91.8 -21.02 0.1528 0.2460 0.450 (0.288-0.612) -7.25 
rs9268176 97.3 -22.24 0.1462 0.2411 0.448 (0.282-0.615) -6.91 
rs7341328 91.8 -21.02 0.1528 0.2460 0.450 (0.288-0.612) -7.25 
rs9268192 91.8 -21.02 0.1528 0.2460 0.450 (0.288-0.612) -7.25 
rs9268197 97.3 -22.24 0.1462 0.2411 0.448 (0.282-0.615) -6.91 
rs9268198 91.8 -21.02 0.1528 0.2460 0.450 (0.288-0.612) -7.25 
rs3864302 97.9 -22.36 0.1541 0.2508 0.453 (0.290-0.617) -7.25 
rs9268202 96.8 -22.13 0.1462 0.2408 0.452 (0.285-0.620) -6.90 
rs6934429 91.3 -20.92 0.1528 0.2457 0.454 (0.290-0.617) -7.24 
rs6934776 96.8 -22.13 0.1462 0.2408 0.452 (0.285-0.620) -6.90 
rs6939410 96.4 -22.02 0.1462 0.2406 0.449 (0.280-0.618) -6.74 
rs1018434 88.0 -20.19 0.1544 0.2457 0.461 (0.293-0.630) -7.10 
rs1018433 90.8 -20.81 0.1528 0.2454 0.451 (0.286-0.616) -7.09 
rs1018430 97.6 -22.29 0.1538 0.2503 0.441 (0.278-0.605) -6.91 
rs9268212 96.4 -22.02 0.1462 0.2406 0.449 (0.280-0.618) -6.74 
rs9268213 90.8 -20.81 0.1528 0.2454 0.451 (0.286-0.616) -7.09 
rs9268215 90.8 -20.81 0.1528 0.2454 0.451 (0.286-0.616) -7.09 
rs6909790 90.8 -20.81 0.1528 0.2454 0.451 (0.286-0.616) -7.09 
rs6915455 90.8 -20.81 0.1528 0.2454 0.451 (0.286-0.616) -7.09 
rs521828 92.6 -21.2 0.1767 0.2745 0.431 (0.251-0.611) -5.56 
rs3129924 67.9 -15.77 0.1182 0.1907 0.443 (0.254-0.633) -5.33 
rs3129925 67.9 -15.77 0.1182 0.1907 0.443 (0.254-0.633) -5.33 
rs3129926 67.9 -15.77 0.1182 0.1907 0.443 (0.254-0.633) -5.33 
rs2143461 67.9 -15.77 0.1182 0.1907 0.443 (0.254-0.633) -5.33 
rs3129939 67.9 -15.77 0.1182 0.1907 0.443 (0.254-0.633) -5.33 
rs3129942 80.3 -18.48 0.161 0.2489 0.426 (0.238-0.615) -5.04 
rs3129943 73.5 -16.99 0.1698 0.2551 0.435 (0.246-0.624) -5.19 
rs2050190 106.0 -24.12 0.1984 0.3071 0.417 (0.256-0.579) -6.41 
rs3117099 121.6 -27.55 0.1415 0.2478 0.464 (0.306-0.621) -8.07 
rs3129963 133.7 -30.19 0.1123 0.2169 0.475 (0.302-0.647) -7.18 
rs9268528 178.3 -39.95 0.5327 0.3723 0.451 (0.281-0.621) -6.73 
rs6930571 127.6 -28.87 0.1097 0.2109 0.518 (0.349-0.686) -8.77 
rs9268530 126.0 -28.51 0.1097 0.2101 0.517 (0.349-0.686) -8.74 
rs9268534 126.0 -28.51 0.1097 0.2101 0.517 (0.349-0.686) -8.74 
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rs6908065 124.5 -28.19 0.1094 0.2091 0.518 (0.348-0.687) -8.67 
rs6930933 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs3135382 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs2001097 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs3135380 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs9268542 171.7 -38.51 0.5330 0.3755 0.444 (0.274-0.615) -6.51 
rs3135378 124.8 -28.25 0.1104 0.2104 -1.13 (-1.63--0.631) -5.04 
rs3135376 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs3135375 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs3135374 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs3135372 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs2187820 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs9268556 171.7 -38.51 0.5330 0.3755 0.444 (0.274-0.615) -6.51 
rs2395161 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs2395162 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs2395164 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs2213580 125.7 -28.45 0.1101 0.2104 0.517 (0.348-0.686) -8.70 
rs9268557 221.8 -49.43 0.3233 0.5008 0.511 (0.381-0.641) -13.85 
rs3135363 132.5 -29.94 0.1739 0.2923 0.464 (0.295-0.633) -7.12 
rs3135356 123.1 -27.87 0.1097 0.2088 -1.112 (-1.592--0.631) -5.23 
rs3135351 123.1 -27.87 0.1097 0.2088 -1.112 (-1.592--0.631) -5.23 
rs2395171 123.7 -28.00 0.1104 0.2099 0.514 (0.353-0.674) -9.47 
rs3135393 124.5 -28.19 0.1119 0.2123 0.474 (0.310-0.638) -7.84 
rs3129884 124.3 -28.13 0.1129 0.2134 0.475 (0.312-0.639) -7.91 
rs3129887 131.3 -29.67 0.1123 0.2158 0.465 (0.305-0.624) -7.95 
rs8084 236.8 -52.72 0.2868 0.4677 0.427 (0.287-0.567) -8.69 
rs2239806 124.3 -28.13 0.1129 0.2134 0.475 (0.312-0.639) -7.91 
rs2239805 124.5 -28.19 0.1119 0.2123 0.474 (0.310-0.638) -7.84 
rs7192 217.9 -48.60 0.2667 0.4378 0.434 (0.297-0.570) -9.33 
rs7195 216.3 -48.23 0.2673 0.4378 0.433 (0.296-0.570) -9.26 
rs1051336 124.3 -28.13 0.1129 0.2134 0.475 (0.312-0.639) -7.91 
rs1041885 124.3 -28.13 0.1129 0.2134 0.475 (0.312-0.639) -7.91 
rs2213586 217.1 -48.41 0.2670 0.4378 0.434 (0.297-0.570) -9.33 
rs2213585 217.1 -48.41 0.2670 0.4378 0.434 (0.297-0.570) -9.33 
rs2227139 217.1 -48.41 0.2670 0.4378 0.434 (0.297-0.570) -9.33 
rs3763327 215.6 -48.09 0.2673 0.4375 0.431 (0.294-0.568) -9.13 
rs3129890 163.1 -36.62 0.1667 0.2980 0.488 (0.348-0.629) -11.00 
rs3129891 128.6 -29.08 0.1264 0.2325 0.490 (0.320-0.659) -7.84 
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rs7754768 225.7 -50.28 0.2733 0.4483 0.457 (0.326-0.589) -10.98 
rs9268832 224.7 -50.07 0.2695 0.4437 0.472 (0.342-0.601) -12.03 
rs9268856 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs9268861 120.6 -27.33 0.1377 0.2427 0.498 (0.335-0.662) -8.65 
rs9268862 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs4428528 170.2 -38.18 0.1638 0.2977 0.476 (0.338-0.614) -10.88 
rs7766843 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs7747521 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs9268878 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs9268885 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs9268976 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs9268977 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs9268980 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs9269043 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs2157338 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs2187823 171.1 -38.37 0.1635 0.2977 0.477 (0.340-0.615) -10.95 
rs1964995 355.7 -78.62 0.3365 0.5636 0.450 (0.304-0.596) -8.80 
AA_DRB1_233_32656004_R 232.0 -51.67 0.1891 0.3551 0.368 (0.225-0.512) -6.33 
AA_DRB1_233_32656004_T 273.4 -60.68 0.2214 0.4089 0.420 (0.285-0.554) -9.03 
SNP_DRB1_32656004 231.0 -51.45 0.1929 0.3586 0.394 (0.251-0.536) -7.23 
SNP_DRB1_32656559 419.4 -92.47 0.5772 0.3311 0.516 (0.349-0.684) -8.80 
SNP_DRB1_32657334 354.8 -78.43 0.3370 0.5642 0.452 (0.306-0.597) -8.89 
AA_DRB1_180_32657338_L 419.9 -92.58 0.4329 0.2031 0.618 (0.417-0.819) -8.80 
AA_DRB1_180_32657338_V 329.4 -72.90 0.4527 0.2439 0.511 (0.298-0.724) -5.60 
SNP_DRB1_32657339 419.1 -92.41 0.4329 0.2034 0.618 (0.417-0.819) -8.81 
SNP_DRB1_32657430 274.4 -60.90 0.2240 0.4121 0.420 (0.285-0.554) -9.06 
AA_DRB1_149_32657431_H 272.6 -60.51 0.2218 0.4095 0.419 (0.285-0.553) -9.04 
AA_DRB1_149_32657431_Q 279.9 -62.10 0.2216 0.411 0.419 (0.285-0.552) -9.08 
SNP_DRB1_32657475 274.4 -60.90 0.2240 0.4121 0.420 (0.285-0.554) -9.06 
AA_DRB1_120_32657518_N 455.7 -100.40 0.4517 0.2104 0.579 (0.371-0.788) -7.26 
AA_DRB1_120_32657518_S 454.0 -100.00 0.4522 0.2102 0.581 (0.372-0.789) -7.31 
SNP_DRB1_32657518 454.9 -100.20 0.4518 0.2107 0.580 (0.371-0.788) -7.27 
SNP_DRB1_32657526 233.1 -51.89 0.2440 0.4186 0.420 (0.279-0.560) -8.33 
AA_DRB1_96_32657590_H 343.6 -75.99 0.2867 0.5079 0.442 (0.297-0.586) -8.69 
AA_DRB1_96_32657590_HE 280.4 -62.21 0.5661 0.3634 0.412 (0.233-0.592) -5.17 
AA_DRB1_96_32657590_HQ 417.7 -92.10 0.5787 0.3324 0.516 (0.348-0.684) -8.78 
AA_DRB1_96_32657590_Hx 344.1 -76.10 0.2884 0.5095 0.437 (0.291-0.583) -8.38 
AA_DRB1_96_32657590_Y 420.4 -92.69 0.4331 0.2033 0.618 (0.418-0.819) -8.83 
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AA_DRB1_96_32657590_YE 425.9 -93.89 0.5799 0.3312 0.508 (0.338-0.678) -8.33 
AA_DRB1_96_32657590_Yx 419.6 -92.54 0.4342 0.2039 0.618 (0.418-0.819) -8.83 
SNP_DRB1_32657591_A 413.8 -91.27 0.4306 0.2023 0.615 (0.413-0.818) -8.62 
SNP_DRB1_32657591_G 418.3 -92.25 0.5769 0.3311 0.516 (0.348-0.683) -8.77 
AA_DRB1_74_32659926_AE 131.6 -29.73 0.1453 0.2578 0.546 (0.405-0.686) -13.59 
AA_DRB1_74_32659926_AL 94.4 -21.59 0.1586 0.2578 0.498 (0.332-0.664) -8.36 
AA_DRB1_74_32659926_AQ 81.9 -18.85 0.1343 0.2214 0.468 (0.297-0.639) -7.10 
AA_DRB1_74_32659926_RQ 93.1 -21.31 0.1249 0.2135 0.492 (0.322-0.662) -7.87 
SNP_DRB1_32659926_CT 91.2 -20.88 0.1610 0.2589 0.499 (0.331-0.666) -8.29 
SNP_DRB1_32659927 127.9 -28.94 0.1474 0.2589 0.547 (0.405-0.688) -13.50 
AA_DRB1_73_32659929 93.1 -21.31 0.1249 0.2135 0.492 (0.322-0.662) -7.87 
SNP_DRB1_32659929 93.1 -21.31 0.1249 0.2135 0.492 (0.322-0.662) -7.87 
SNP_DRB1_32659937 226.7 -50.51 0.1902 0.3568 0.427 (0.291-0.562) -9.14 
AA_DRB1_70_32659938_D 226.7 -50.51 0.1902 0.3568 0.427 (0.291-0.562) -9.14 
AA_DRB1_70_32659938_Q 198.5 -44.35 0.2369 0.3994 0.414 (0.270-0.557) -7.76 
SNP_DRB1_32659939 226.7 -50.51 0.1902 0.3568 0.427 (0.291-0.562) -9.14 
AA_DRB1_67_32659947_I 186.8 -41.79 0.2344 0.3916 0.409 (0.267-0.551) -7.81 
AA_DRB1_67_32659947_L 276.1 -61.28 0.3103 0.5133 0.451 (0.308-0.595) -9.14 
SNP_DRB1_32659948_G 276.1 -61.28 0.3103 0.5133 0.451 (0.308-0.595) -9.14 
SNP_DRB1_32659948_T 186.8 -41.79 0.2344 0.3916 0.409 (0.267-0.551) -7.81 
AA_DRB1_47_32660007 261.0 -57.99 0.2912 0.4833 0.371 (0.218-0.525) -5.66 
SNP_DRB1_32660007 261.0 -57.99 0.2912 0.4833 0.371 (0.218-0.525) -5.66 
AA_DRB1_37_32660037_N 169.0 -37.91 0.1506 0.2836 0.451 (0.295-0.607) -7.81 
AA_DRB1_37_32660037_NF 243.6 -54.19 0.2093 0.3864 0.465 (0.333-0.598) -11.22 
AA_DRB1_37_32660037_NL 172.0 -38.57 0.1668 0.3050 0.428 (0.275-0.580) -7.43 
AA_DRB1_37_32660037_SY 255.9 -56.88 0.2228 0.4067 0.441 (0.304-0.578) -9.58 
AA_DRB1_37_32660037_Y 289.1 -64.11 0.5114 0.3057 0.463 (0.272-0.653) -5.69 
AA_DRB1_37_32660037_YL 270.2 -60.00 0.5276 0.3276 0.449 (0.263-0.635) -5.64 
SNP_DRB1_32660038_A 176.5 -39.55 0.1644 0.3037 0.428 (0.277-0.580) -7.53 
SNP_DRB1_32660038_T 169.0 -37.91 0.1506 0.2836 0.451 (0.295-0.607) -7.81 
HLA_DRB1_04 419.4 -92.48 0.4339 0.2040 0.619 (0.418-0.819) -8.85 
HLA_DRB1_0401 257.7 -57.27 0.2908 0.1294 0.711 (0.466-0.956) -7.91 
SNP_DRB1_32660045 338.4 -74.84 0.3222 0.5472 0.475 (0.335-0.616) -10.48 
AA_DRB1_33_32660049 419.1 -92.42 0.4331 0.2038 0.619 (0.418-0.819) -8.85 
SNP_DRB1_32660050 419.1 -92.42 0.4331 0.2038 0.619 (0.418-0.819) -8.85 
AA_DRB1_32_32660052 158.0 -35.51 0.1813 0.3159 0.424 (0.265-0.583) -6.74 
SNP_DRB1_32660053 157.6 -35.43 0.1813 0.3157 0.422 (0.263-0.582) -6.67 
AA_DRB1_13_32660109_H 419.1 -92.42 0.4331 0.2038 0.619 (0.418-0.819) -8.85 
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AA_DRB1_13_32660109_HF 470.4 -103.60 0.6172 0.3553 0.506 (0.349-0.663) -9.61 
AA_DRB1_13_32660109_HG 290.4 -64.40 0.4751 0.2737 0.486 (0.278-0.694) -5.35 
AA_DRB1_13_32660109_HY 277.4 -61.56 0.4797 0.2844 0.457 (0.258-0.656) -5.17 
AA_DRB1_13_32660109_RH 250.3 -55.65 0.5476 0.3570 0.415 (0.233-0.597) -5.10 
AA_DRB1_13_32660109_S 212.1 -47.32 0.1798 0.3373 0.409 (0.263-0.556) -7.34 
AA_DRB1_13_32660109_SG 275.1 -61.06 0.2242 0.4126 0.417 (0.282-0.551) -8.90 
AA_DRB1_13_32660109_SR 267.9 -59.48 0.2957 0.4925 0.425 (0.280-0.569) -8.07 
AA_DRB1_13_32660109_SRG 354.1 -78.27 0.3386 0.5660 0.447 (0.299-0.595) -8.51 
AA_DRB1_13_32660109_SRY 358.6 -79.26 0.3424 0.5741 0.485 (0.340-0.631) -10.18 
AA_DRB1_13_32660109_SY 279.3 -61.98 0.2264 0.4192 0.445 (0.311-0.580) -10.06 
AA_DRB1_13_32660109_SYG 354.3 -78.31 0.2706 0.4932 0.443 (0.304-0.582) -9.42 
SNP_DRB1_32660109_G 212.1 -47.32 0.1798 0.3373 0.409 (0.263-0.556) -7.34 
SNP_DRB1_32660109_GC 354.1 -78.27 0.3386 0.5660 0.447 (0.299-0.595) -8.51 
SNP_DRB1_32660109_T 277.4 -61.56 0.4797 0.2844 0.457 (0.258-0.656) -5.17 
SNP_DRB1_32660110_AC 245.0 -54.50 0.5441 0.3561 0.412 (0.229-0.594) -5.00 
SNP_DRB1_32660110_AT 283.4 -62.86 0.4708 0.2725 0.488 (0.281-0.695) -5.43 
SNP_DRB1_32660110_G 419.1 -92.42 0.4331 0.2038 0.619 (0.418-0.819) -8.85 
SNP_DRB1_32660111 419.1 -92.42 0.4331 0.2038 0.619 (0.418-0.819) -8.85 
AA_DRB1_12_32660112 275.1 -61.06 0.2242 0.4126 0.417 (0.282-0.551) -8.90 
SNP_DRB1_32660112 275.1 -61.06 0.2242 0.4126 0.417 (0.282-0.551) -8.90 
AA_DRB1_11_32660115_PV 282.0 -62.57 0.5665 0.3642 0.411 (0.232-0.590) -5.16 
AA_DRB1_11_32660115_S 275.1 -61.06 0.2242 0.4126 0.417 (0.282-0.551) -8.90 
AA_DRB1_11_32660115_SD 264.2 -58.68 0.2416 0.4286 0.418 (0.281-0.555) -8.65 
AA_DRB1_11_32660115_SG 354.3 -78.31 0.2706 0.4932 0.443 (0.304-0.582) -9.42 
AA_DRB1_11_32660115_SGD 344.7 -76.21 0.2881 0.5092 0.440 (0.296-0.585) -8.64 
AA_DRB1_11_32660115_SGL 282.1 -62.58 0.5822 0.3789 0.409 (0.236-0.582) -5.43 
AA_DRB1_11_32660115_SP 354.1 -78.27 0.3386 0.566 0.447 (0.299-0.595) -8.51 
AA_DRB1_11_32660115_SPD 348.1 -76.96 0.3561 0.5820 0.450 (0.297-0.602) -8.14 
AA_DRB1_11_32660115_SPG 466.3 -102.70 0.6148 0.3535 0.508 (0.351-0.666) -9.58 
AA_DRB1_11_32660115_V 454.7 -100.20 0.4518 0.2109 0.580 (0.371-0.789) -7.28 
AA_DRB1_11_32660115_VD 448.6 -98.83 0.4691 0.2268 0.575 (0.382-0.768) -8.28 
AA_DRB1_11_32660115_VL 467.3 -102.90 0.5999 0.3394 0.498 (0.329-0.666) -8.18 
SNP_DRB1_32660115_A 467.3 -102.90 0.5999 0.3394 0.498 (0.329-0.666) -8.18 
SNP_DRB1_32660115_G 354.1 -78.27 0.3386 0.5660 0.447 (0.299-0.595) -8.51 
SNP_DRB1_32660115_GC 466.3 -102.70 0.6148 0.3535 0.508 (0.351-0.666) -9.58 
SNP_DRB1_32660115_GT 348.1 -76.96 0.3561 0.5820 0.450 (0.297-0.602) -8.14 
SNP_DRB1_32660116_A 275.1 -61.06 0.2242 0.4126 0.417 (0.282-0.551) -8.90 
SNP_DRB1_32660117 275.1 -61.06 0.2242 0.4126 0.417 (0.282-0.551) -8.90 
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AA_DRB1_10_32660118_Q 239.0 -53.19 0.2414 0.4186 0.414 (0.273-0.555) -8.04 
AA_DRB1_10_32660118_Y 275.1 -61.06 0.2242 0.4126 0.417 (0.282-0.551) -8.90 
SNP_DRB1_32660119_A 280.1 -62.14 0.2216 0.411 0.417 (0.283-0.551) -9.00 
SNP_DRB1_32660119_G 233.3 -51.95 0.2443 0.4191 0.417 (0.276-0.558) -8.20 
SNP_DRB1_32665401 192.5 -43.04 0.2237 0.3785 0.395 (0.242-0.548) -6.37 
AA_DRB1_-16_32665457_A 232.7 -51.81 0.2445 0.4190 0.417 (0.276-0.558) -8.20 
AA_DRB1_-16_32665457_V 187.3 -41.90 0.2144 0.3662 0.378 (0.223-0.533) -5.73 
SNP_DRB1_32665457 233.7 -52.03 0.2442 0.4191 0.417 (0.276-0.558) -8.19 
AA_DRB1_-24_32665481_F 411.1 -90.67 0.4286 0.2025 0.617 (0.417-0.818) -8.79 
AA_DRB1_-24_32665481_L 311.9 -69.09 0.4570 0.2527 0.498 (0.283-0.712) -5.27 
SNP_DRB1_32665482 410.8 -90.61 0.4288 0.2029 0.618 (0.417-0.818) -8.81 
AA_DRB1_-25_32665484_K 232.7 -51.81 0.2445 0.4190 0.417 (0.276-0.558) -8.20 
AA_DRB1_-25_32665484_R 187.3 -41.90 0.2144 0.3662 0.378 (0.223-0.533) -5.73 
SNP_DRB1_32665484 233.0 -51.87 0.2445 0.4191 0.417 (0.276-0.558) -8.20 
rs477515 263.9 -58.62 0.4802 0.2899 0.453 (0.256-0.649) -5.21 
rs2858867 131.1 -29.63 0.2318 0.3586 0.420 (0.270-0.570) -7.36 
rs660895 317.8 -70.35 0.4516 0.2473 0.508 (0.297-0.720) -5.62 
rs521539 317.8 -70.35 0.4516 0.2473 0.508 (0.297-0.720) -5.62 
rs3104413 413.4 -91.18 0.4296 0.2029 0.621 (0.422-0.820) -9.05 
rs6931277 413.4 -91.18 0.4296 0.2029 0.621 (0.423-0.820) -9.07 
rs9271588 322.3 -71.33 0.3204 0.5356 0.424 (0.276-0.571) -7.73 
rs9272219 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
SNP_DQA1_32713249 109.7 -24.94 0.1598 0.2640 0.405 (0.233-0.577) -5.39 
HLA_DQA1_03 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
HLA_DQA1_0301 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
SNP_DQA1_32717072 187.2 -41.89 0.5000 0.3371 0.443 (0.260-0.625) -5.70 
SNP_DQA1_32717108 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
SNP_DQA1_32717120 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
AA_DQA1_26_32717128 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
SNP_DQA1_32717128 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
SNP_DQA1_32717151 325.3 -72.00 0.3274 0.5440 0.448 (0.305-0.591) -9.10 
AA_DQA1_34_32717152 325.3 -72.00 0.3274 0.5440 0.448 (0.305-0.591) -9.10 
AA_DQA1_40_32717170 108.5 -24.69 0.1604 0.2640 0.397 (0.222-0.571) -5.08 
SNP_DQA1_32717170 108.5 -24.69 0.1604 0.2640 0.397 (0.222-0.571) -5.08 
SNP_DQA1_32717190_C 160.9 -36.14 0.2063 0.3441 0.483 (0.345-0.620) -11.25 
SNP_DQA1_32717190_T 108.5 -24.69 0.1604 0.2640 0.397 (0.222-0.571) -5.08 
AA_DQA1_47_32717191_C 108.8 -24.74 0.1604 0.2642 0.397 (0.223-0.571) -5.12 
AA_DQA1_47_32717191_Q 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
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AA_DQA1_47_32717191_RQ 160.7 -36.10 0.2063 0.3440 0.481 (0.343-0.618) -11.11 
SNP_DQA1_32717192 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
AA_DQA1_50_32717200_V 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
SNP_DQA1_32717201 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
SNP_DQA1_32717202 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
AA_DQA1_51_32717203 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
SNP_DQA1_32717207 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
SNP_DQA1_32717208 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
AA_DQA1_53_32717209_Q 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
SNP_DQA1_32717217_A 397.6 -87.73 0.4469 0.2209 0.580 (0.379-0.780) -7.84 
SNP_DQA1_32717217_x 160.9 -36.14 0.2063 0.3441 0.483 (0.345-0.620) -11.25 
AA_DQA1_56_32717218_R 398.1 -87.86 0.4469 0.2208 0.580 (0.379-0.780) -7.85 
AA_DQA1_56_32717218_x 161.1 -36.18 0.2063 0.3441 0.482 (0.344-0.619) -11.19 
SNP_DQA1_32717219_A 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
SNP_DQA1_32717219_x 160.7 -36.10 0.2063 0.3440 0.481 (0.343-0.618) -11.11 
SNP_DQA1_32717277_C 161.9 -36.36 0.2063 0.3445 0.481 (0.344-0.618) -11.22 
SNP_DQA1_32717277_G 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
AA_DQA1_76_32717278_L 161.9 -36.36 0.2063 0.3445 0.481 (0.344-0.618) -11.22 
AA_DQA1_76_32717278_V 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
SNP_DQA1_32718379 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
AA_DQA1_187_32718380_A 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
AA_DQA1_187_32718380_T 399.3 -88.11 0.4469 0.2206 0.580 (0.380-0.780) -7.85 
SNP_DQA1_32718414 181.0 -40.54 0.2129 0.3609 0.376 (0.230-0.522) -6.37 
SNP_DQA1_32718423 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
rs9273012 108.5 -24.69 0.1604 0.2640 0.395 (0.220-0.569) -5.02 
SNP_DQB1_32737205 79.8 -18.38 0.1062 0.1828 0.535 (0.322-0.748) -6.06 
SNP_DQB1_32737837 267.7 -59.45 0.2588 0.4490 0.440 (0.306-0.574) -9.92 
HLA_DQB1_02 79.1 -18.22 0.1065 0.1827 0.535 (0.322-0.748) -6.07 
HLA_DQB1_03 241.6 -53.76 0.5239 0.3382 0.444 (0.262-0.625) -5.79 
HLA_DQB1_0302 227.9 -50.76 0.2938 0.1443 0.673 (0.426-0.921) -7.00 
AA_DQB1_74_32740615_A 78.9 -18.19 0.1065 0.1827 0.534 (0.320-0.747) -6.02 
SNP_DQB1_32740623 78.9 -18.19 0.1065 0.1827 0.534 (0.320-0.747) -6.02 
AA_DQB1_71_32740624_K 78.9 -18.19 0.1065 0.1827 0.534 (0.320-0.747) -6.02 
AA_DQB1_71_32740624_KD 110.5 -25.13 0.1300 0.2282 -1.220 (-1.730--0.710) -5.56 
SNP_DQB1_32740624 110.5 -25.13 0.1300 0.2282 -1.220 (-1.730--0.710) -5.56 
AA_DQB1_67_32740636 100.4 -22.91 0.1359 0.2303 -1.258 (-1.797--0.719) -5.32 
SNP_DQB1_32740637 100.4 -22.91 0.1359 0.2303 -1.258 (-1.797--0.719) -5.32 
SNP_DQB1_32740638 100.4 -22.91 0.1359 0.2303 -1.258 (-1.797--0.719) -5.32 
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AA_DQB1_66_32740639 100.4 -22.91 0.1359 0.2303 -1.258 (-1.797--0.719) -5.32 
AA_DQB1_55_32740672_L 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
AA_DQB1_55_32740672_P 241.5 -53.73 0.5239 0.3383 0.443 (0.262-0.625) -5.78 
SNP_DQB1_32740672_A 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740672_G 241.5 -53.73 0.5239 0.3383 0.443 (0.262-0.625) -5.78 
AA_DQB1_52_32740681 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740681 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
AA_DQB1_47_32740696 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740696 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
AA_DQB1_46_32740699 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740699 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740722 241.6 -53.75 0.5240 0.3382 0.443 (0.262-0.625) -5.78 
AA_DQB1_37_32740726_I 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740726 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740727_T 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740731 77.9 -17.97 0.1074 0.1833 0.525 (0.317-0.734) -6.09 
AA_DQB1_30_32740747_S 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740747 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740748_T 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
AA_DQB1_28_32740753 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740753 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
SNP_DQB1_32740773_C 113.1 -25.69 0.1285 0.2278 -1.236 (-1.752--0.720) -5.58 
SNP_DQB1_32740773_T 79.1 -18.22 0.1065 0.1827 0.535 (0.321-0.748) -6.05 
AA_DQB1_-10_32742295_A 112.6 -25.59 0.1330 0.2345 0.492 (0.320-0.665) -7.67 
AA_DQB1_-10_32742295_S 79.4 -18.30 0.1064 0.1827 0.536 (0.323-0.748) -6.09 
SNP_DQB1_32742296_A 79.4 -18.30 0.1064 0.1827 0.536 (0.323-0.748) -6.09 
SNP_DQB1_32742296_C 213.8 -47.69 0.1752 0.3306 0.472 (0.341-0.603) -11.80 
rs3891175 79.5 -18.31 0.1063 0.1827 0.536 (0.323-0.748) -6.09 
rs9275184 231.7 -51.60 0.3014 0.1469 0.687 (0.452-0.922) -7.99 
rs9275206 230.2 -51.27 0.2943 0.1441 0.674 (0.426-0.921) -7.02 
rs9275224 277.3 -61.55 0.2767 0.4723 0.438 (0.303-0.573) -9.74 
rs2858324 238.3 -53.03 0.2428 0.4192 0.394 (0.255-0.534) -7.53 
rs6457617 274.5 -60.92 0.2833 0.4784 0.446 (0.312-0.580) -10.18 
rs6457620 274.5 -60.92 0.2833 0.4784 0.446 (0.312-0.580) -10.18 
rs2647012 238.5 -53.08 0.2425 0.4189 0.393 (0.254-0.533) -7.48 
rs9275334 230.2 -51.27 0.2943 0.1441 0.674 (0.426-0.921) -7.02 
rs17427599 49.5 -11.70 0.3390 0.2613 0.485 (0.272-0.698) -5.10 
rs1612904 218.3 -48.68 0.2305 0.3971 0.389 (0.247-0.531) -7.10 
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rs2856717 236.3 -52.59 0.2418 0.4173 0.391 (0.251-0.531) -7.37 
rs9275495 230.2 -51.27 0.2943 0.1441 0.674 (0.426-0.921) -7.02 
rs9275516 287.7 -63.81 0.2648 0.4628 0.414 (0.274-0.553) -8.20 
rs9275530 228.2 -50.83 0.2933 0.1439 0.674 (0.426-0.921) -7.02 
rs9275532 230.2 -51.27 0.2943 0.1441 0.674 (0.426-0.921) -7.02 
rs6932517 282.7 -62.72 0.2667 0.4631 0.415 (0.276-0.555) -8.26 
rs7764856 349.1 -77.18 0.3748 0.6006 0.480 (0.328-0.633) -9.16 
rs7454108 226.3 -50.42 0.2915 0.1430 0.693 (0.454-0.931) -7.91 
rs3957146 226.3 -50.42 0.2915 0.1430 0.693 (0.454-0.931) -7.91 
rs9275596 214.6 -47.87 0.2330 0.3984 0.384 (0.241-0.527) -6.83 
rs3998159 228.9 -50.98 0.2925 0.1430 0.697 (0.462-0.932) -8.22 
rs9275599 205.2 -45.81 0.2818 0.1417 0.665 (0.410-0.920) -6.49 
rs9784858 78.4 -18.07 0.2060 0.1269 0.753 (0.547-0.959) -12.08 
rs10484565 77.5 -17.87 0.2025 0.1245 0.732 (0.504-0.961) -9.49 
rs241409 63.1 -14.72 0.1865 0.1180 0.718 (0.482-0.955) -8.59 
rs241407 64.3 -14.97 0.1878 0.1183 0.720 (0.485-0.955) -8.71 
rs9277628 17.8 -4.62 0.1787 0.1405 0.637 (0.356-0.918) -5.06 
 
